“The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes As Effectively As Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s629, https://doi.org/10.25251/xbb5zx93.